In Q1 FY2026, X4 Pharmaceuticals reported revenue of $2.5 million, a 178% increase year-over-year, driven by license and other revenue. Net loss widened to $20.2 million from $0.3 million in the prior year, while operating loss increased to $20.3 million. Diluted EPS was -$0.16, compared to -$0.03 a year ago. The company held $216.9 million in cash, $168.5 million in equity, and $75.0 million in long-term debt.
•Revenue surged 178% YoY to $2.5M, primarily from license and other revenue.
•Net loss expanded to $20.2M from $0.3M, with operating loss of $20.3M.
•Diluted EPS was -$0.16, down from -$0.03 in Q1 FY2025.
•Cash and equivalents stood at $216.9M, with long-term debt of $75.0M.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
X4 Pharmaceuticals, Inc., a biopharmaceutical company focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau.
Its portfolio also includes Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand, and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for rare diseases of the immune system. Its lead product candidate is XOLREMDI, an orally administered small-molecule selective antagonist of the chemokine receptor CXCR4. XOLREMDI is currently in a Phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a rare primary immunodeficiency disease. The company also has a portfolio of partnerships, including a license agreement with Abbisko Therapeutics Co Ltd. for the manufacture and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Additionally, X4 has agreements with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand, and with Genzyme Corporation for the CXCR4 receptor to develop and commercialize products for all therapeutic, prophylactic, and diagnostic uses.
Where is X4 Pharmaceuticals (XFOR) listed and what currency does it trade in?
X4 Pharmaceuticals, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol XFOR. The company trades in United States Dollars (USD), which is the official currency of the United States. As a Nasdaq-listed company, XFOR is subject to the reporting and regulatory requirements of the U.S. Securities and Exchange Commission (SEC). The NasdaqCM is a U.S.-based stock exchange that primarily lists small-cap and emerging growth companies, providing them with access to public capital markets. Investors can buy and sell shares of X4 Pharmaceuticals through brokerage accounts that offer access to U.S. equities, and the stock price is quoted in USD.
What sector and industry does X4 Pharmaceuticals (XFOR) belong to?
X4 Pharmaceuticals, Inc. operates in the Healthcare sector and specifically within the Biotechnology industry. Biotechnology companies use biological processes, organisms, or cellular systems to develop products and technologies for healthcare, agriculture, and other fields. In the case of X4, the company focuses on developing novel therapeutics for rare diseases of the immune system, which falls under the broader biotechnology umbrella. The Biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight. Companies in this sector often rely on partnerships, licensing agreements, and clinical trial results to advance their pipelines. X4's specialization in rare immune diseases positions it within a niche area of biotechnology that addresses unmet medical needs.
Where is X4 Pharmaceuticals (XFOR) headquartered and what markets does it serve?
X4 Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts, United States. Boston is a major hub for biotechnology and pharmaceutical research, providing access to a skilled workforce and academic institutions. The company primarily serves the U.S. market but has international reach through licensing and partnership agreements. For instance, X4 has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Additionally, the company has partnered with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. X4 also has an agreement with Genzyme Corporation for the CXCR4 receptor, which covers all therapeutic, prophylactic, and diagnostic uses globally. These partnerships enable X4 to expand its geographic footprint without directly operating in all regions.
What is the business model of X4 Pharmaceuticals (XFOR) and how does it generate revenue?
X4 Pharmaceuticals, Inc. is a biopharmaceutical company that generates revenue primarily through the development and commercialization of novel therapeutics for rare immune diseases. Its business model involves advancing its lead product candidate, XOLREMDI, through clinical trials and, upon regulatory approval, marketing it to patients and healthcare providers. The company also enters into strategic licensing and partnership agreements to expand the reach of its products. For example, X4 has a license agreement with Abbisko Therapeutics Co Ltd. for the manufacture and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau, which may involve upfront payments, milestone payments, and royalties on sales. Similarly, partnerships with Norgine for mavorixafor in Europe, Australia, and New Zealand, and with Genzyme Corporation for the CXCR4 receptor, provide additional revenue streams through similar deal structures. As a clinical-stage company, X4 may also generate revenue from research collaborations and grants, but its primary focus remains on bringing XOLREMDI to market to address the unmet needs of patients with WHIM syndrome.